Insider buying last 90 days
No open-market insider purchases were filed for LFST in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every LFST insider filing, plotted on the chart in Gekko.Open LFST in Gekko
NASDAQ: LFST
LifeStance Health (LFST) Stock Analysis & Forecast
Sep 28 close
$11.840.00 (0.0%)
Gekko Brief
AI summaryLifeStance Health draws attention this week mainly from an updated analyst price target, with coverage citing a raised outlook and buyback activity behind the increase to $14.20. Separate commentary flagged weak near and mid-term sentiment alongside a strong long-term outlook for the stock. Beyond this, a CTO share sale worth over $541,000 was reported as routine, alongside other filing activity including a Form 4 and share gifts by CEO David Bourdon into two trusts.
LFST closed at $11.84, sitting between its 50-day average of $11.97 and its 200-day average of $8.70, reflecting a mixed trend picture. The GekkoIndex reads 64.5, placing the stock in the Accumulation zone. Price stands 20.2% below Gekko Fair Value of $14.84, a gap that bears watching. Over the past year the stock has returned 125.1%, though the one-month return sits at -3.7%.
The next earnings date falls on 5 November 2026, 37 days out and beyond a typical 20-trading-day holding window; the prior report on 6 August 2026 saw EPS of $0.06 versus a $0.03 estimate, with an average absolute reaction of 9.1% historically. No insider, Congress or unusual options activity appears in their respective 90-day and 30-day windows. Seasonality over the next 20 trading days has averaged -10.2% across 5 years, rising in only 1 of them, a contrast worth noting against the current Accumulation reading and the gap to fair value.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
LifeStance Health price vs fair value
Close $11.84200-day averageGekko Fair Value $14.84
LifeStance Health quick facts
- Market cap
- $4.59B
- P/E ratio
- 90.8
- Forward P/E
- 52.6
- EPS, TTM
- $0.13
- Revenue, TTM
- $1.58B
- Profit margin
- 3.2%
- Dividend yield
- —
- Beta
- 1.22
- Volume
- 3.04M avg 5.86M
- 1-year return
- +125.1%
- Typical daily move
- ±4%
- Typical 20-day move
- ±10.3%
- 50-day average
- $11.97
- 200-day average
- $8.70
- Next earnings
- Nov 5 before open
- Shares outstanding
- 380.2M
LifeStance Health swing-trade checklist
LifeStance Health scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed1 headwind
- Trendmixed
Averages disagree
Close $11.84 sits between the 50-day ($11.97) and 200-day ($8.70) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
64.5, Accumulation
Reading 64.5 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
20.2% below
Price is 20.2% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 37 days
Next report Nov 5, 2026, 37 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−10.2% on average
From this point in the calendar, the next 20 trading days averaged −10.2% over 5 years, rising in 1 of them.
See seasonality
A description of current data, not a recommendation. How this page works
LifeStance Health stock chart and price history
LifeStance Health closed at $11.84 on Sep 28, 2026, +125.1% over the past year, inside a 52-week range of $4.77 to $13.56.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −3.7%
- 3 months
- +14.5%
- 6 months
- +87.3%
- 1 year
- +125.1%
The full LFST chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open LFST in Gekko
Follow LifeStance Health through every session
Put LFST on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track LFST in GekkoFree for 7 days. No credit card required.
About LifeStance Health
LifeStance Health operates a network of affiliated practices focused on outpatient mental health care. Clinicians within this network handle psychiatric evaluations, prescribe and manage treatment, run psychological and neuropsychological assessments, and lead sessions that may involve a single patient, a family unit, or a small group. The conditions treated span common struggles like anxiety and depression as well as more difficult diagnoses such as bipolar disorder, eating disorders, psychosis, and post-traumatic stress.
Patients can choose between visiting one of the physical locations or connecting with a provider remotely through a virtual option. The practices under LifeStance serve people at every stage of life, from young children through elderly adults, with a physical footprint spread across 32 states.
LifeStance Health traces its founding to 2017 and runs its headquarters out of Scottsdale, Arizona. The company trades on the NASDAQ under the ticker LFST.
- Listed
- NASDAQ
- Sector
- Health services
- Industry
- Medical/Nursing services
- Website
- lifestance.com
LifeStance Health GekkoIndex: the smart money zone
LifeStance Health’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 64.5, in the Accumulation zone, up 11.3 points over five sessions.
64.5Accumulation
Up 11.3 points over five sessions, from the Neutral zone.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 44 | +1.1% | +5.7% | ||
| Accumulation (current zone) | 194 | +1.3% | +3.0% | ||
| Neutral | 383 | +0.3% | +3.2% | ||
| Distribution | 50 | +1.4% | −0.6% | ||
| Selling | 1 | Too few readings yet | |||
Average LFST share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.3% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the LFST price, zone by zone.Track LFST in Gekko
Is LifeStance Health stock overvalued? Gekko Fair Value
LifeStance Health trades 20.2% below Gekko Fair Value of $14.84, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what LifeStance Health shares are worth, recalculated every trading day.
$14.84
Gekko Fair Value, Sep 26, 2026
20.2% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open LFST in Gekko
LifeStance Health insider and Congress trading
No open-market insider purchases were filed for LifeStance Health, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in LFST were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for LFST, plotted on the chart in Gekko.Open LFST in Gekko
Buybacks
LifeStance Health has been buying back its own shares.
- Latest authorization
- $100.0M, Aug 6, 2026
- Bought back, quarter ended Jun 30, 2026
- $48.52M
- As a share of market cap
- 1.06%
From company filings.
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds LFST.
0added1opened0trimmed2sold out
Which funds are on each side, name by name.Unlock in Gekko
LifeStance Health earnings: next date and track record
LifeStance Health reports on Nov 5, 2026, before the open (37 days away), and beat the EPS estimate in 8 of its last 8 reports.
Next earnings report
Nov 5, 2026
Expected before the open, 37 days away
- EPS estimate
- $0.03
- Revenue estimate
- $431.4M
8 of 8reports beat the EPS estimate
±9.1%average move across the report
6 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 6, 2026 AI summary
- What they said
- LifeStance Health delivered Q2 2026 revenue growth exceeding 26% with adjusted EBITDA margins above 15%, surpassing all guided metrics. The clinician base grew to over 8,500 providers with strong productivity. The company expanded TMS and Spravato specialty services, completed a tuck-in acquisition in Arizona, and is preparing for a new EHR system transition in 2027. Clinical outcomes data showed 75%+ of patients achieved meaningful improvement across diverse populations.
- Guidance
- Management raised full year 2026 guidance across all metrics following Q2 outperformance. The company plans continued geographic expansion into new markets, targeting roughly half of the 150 largest U.S. markets where no presence currently exists, with tuck-in acquisitions as the preferred growth vehicle.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 6, 2026 | $0.06 est $0.03 | $435.4M est $414.6M | +4.5% |
| May 7, 2026 | $0.07 est $0.06 | $403.5M est $387.5M | +4.6% |
| Feb 25, 2026 | $0.09 est $0.05 | $382.2M est $378.4M | −2.5% |
| Nov 6, 2025 | $0.00 est −$0.01 | $363.8M est $378.5M | +30.8% |
| Aug 7, 2025 | −$0.01 est −$0.03 | $345.3M est $358.4M | +12.1% |
| May 7, 2025 | $0.05 est $0.01 | $333.0M est $348.7M | −11.3% |
| Feb 27, 2025 | −$0.01 est −$0.04 | $325.5M est $333.4M | +3.7% |
| Nov 7, 2024 | −$0.02 est −$0.07 | $312.7M est $314.0M | +3.2% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
LifeStance Health stock forecast and analyst price targets
Analysts’ average 12-month price target for LifeStance Health is $14.20, +19.9% from the last close, from 9 firms rating the stock in the last 90 days.
$14.20consensus 12-month target, +19.9% from the last close
Now $11.84Avg $14.20
Low $13High $18
Each firm’s latest rating in the last 90 days: 9 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 25 | Jefferies | $15 | +26.7% |
| Sep 10 | Barclays | $15 | +26.7% |
| Sep 9 | Canaccord Genuity | $15 | +26.7% |
| Aug 21 | William Blair | — | — |
| Aug 19 | BTIG | $18 | +52.0% |
+3.0%average 20-day move after past Accumulation readings
−10.2%average move over the next 20 trading days in the last 5 years
±4%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
LifeStance Health seasonality: the next 20 trading days
Over the next 20 trading days from Sep 26, LifeStance Health averaged −10.2% across the last 5 years, rising in 1 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −4.3% | 2 of 5 |
| Next 10 trading days | −5.3% | 1 of 5 |
| Next 15 trading days | −5.0% | 2 of 5 |
| Next 20 trading days | −10.2% | 1 of 5 |
| Next 30 trading days | −1.2% | 2 of 5 |
For scale, LFST’s typical 20-trading-day move in either direction is about 10.3%.
LifeStance Health market cap and key statistics
LifeStance Health’s market cap is $4.59B, with a P/E ratio of 90.8 and revenue of $1.58B over the last twelve months.
Valuation
- Market cap
- $4.59B
- P/E ratio
- 90.8
- Forward P/E
- 52.6
- EPS, TTM
- $0.13
- Gekko Fair Value
- $14.84
Trading
- Volume
- 3.04M
- Avg volume, 20 days
- 5.86M
- 52-week high
- $13.56
- 52-week low
- $4.77
- Shares outstanding
- 380.2M
Financials
- Revenue, TTM
- $1.58B
- Profit margin
- 3.2%
- Return on equity
- 3.4%
- Quarterly earnings growth, YoY
- +1,927.0%
Risk and income
- Beta
- 1.22
- Typical daily move
- ±4%
- Typical 20-day move
- ±10.3%
LifeStance Health stock news this week
Coverage of LifeStance Health this week reads neutral: 1 positive, 5 neutral and 0 negative headlines.
- Precision Trading with Lifestance Health Group Inc. (LFST) Risk ZonesStock Traders Daily, Sep 27
- Form 4 Lifestance Health Group Inc For: 25 SeptemberInvesting.com India, Sep 25
- Two trusts received share gifts from LifeStance (LFST) CEO David Bourdon, with different trustees named.Stock Titan, Sep 24
- LFST: Raised Outlook And Buybacks Strengthen The Earnings StorySimply Wall Street, Sep 24
- LifeStance Health CTO Sells 42,067 Shares for $541,402Yahoo Finance, Sep 23
- LifeStance Health Group, Inc. (LFST) Stock Price, News, Quote & HistoryYahoo! Finance Canada, Sep 23
LifeStance Health peers
LifeStance Health’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LHLabcorp | Accumulation | 3.9% below |
| GHGuardant Health | Neutral | 0.5% above |
| SOLVSolventum | Neutral | 16.4% below |
| EHCEncompass Health | Neutral | 7.6% above |
| DVADaVita | Accumulation | 15.9% below |
| BTSGBrightSpring Health Services | Accumulation | 7.4% below |
A peer links to its own page where one exists.
LifeStance Health stock FAQ
What is LifeStance Health’s market cap?
LifeStance Health’s market cap is $4.59B at the Sep 28, 2026 close of $11.84, with 380.2M shares outstanding. The shares trade on a P/E ratio of 90.8.
What is the LifeStance Health stock forecast?
The consensus analyst 12-month price target for LifeStance Health is $14.20, +19.9% from the last close. Of the 9 firms that rated the stock in the last 90 days, 8 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is LifeStance Health stock overvalued or undervalued?
On Gekko’s estimate LifeStance Health is undervalued: the Sep 28, 2026 close of $11.84 is 20.2% below Gekko Fair Value of $14.84. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does LifeStance Health report earnings next?
LifeStance Health is expected to report on Nov 5, 2026, before the market opens (37 days away). Analysts expect earnings of $0.03 per share on revenue of $431.4M. LifeStance Health beat the earnings estimate in 8 of its last 8 reports, moving 9.1% on average across the report.
What is LifeStance Health’s 52-week high and low?
LifeStance Health’s 52-week high is $13.56 and its 52-week low is $4.77; it closed at $11.84 on Sep 28, 2026, +125.1% over the past year. Over the last five years the shares peaked at $15.49 on Sep 29, 2021.
Is LifeStance Health stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, fair value and earnings risk), 1 as mixed (trend) and 1 as a headwind (seasonality). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See LifeStance Health the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.